SEC Form 3 · accession 0001144204-15-043241
NAVIDEA BIOPHARMACEUTICALS, INC. · NAVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Tomblyn
Officer — SVP, Chief Med. Officer
Period of report
Jul 2, 2015
Accepted (ET)
Jul 20, 2015 · 2:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000810509
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 100,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.89 | holding | — | — | — | — | Jan 1, 2025 | Common Stock | 100,000 | — | D |
Explanation of responses
- F1Grant of restricted stock on 3/3/2015, vesting 25% per year beginning on first anniversary of award date.
- F2Option vests 25% per year beginning on the first anniversary of date options were awarded (1/1/15).